Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients
Background Remdesivir is the only antiviral agent approved for the treatment of hospitalized coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen. Studies show conflicting results regarding its effect on mortality. Methods In this single center observational study, we included adult hospitalized COVID-19 patients. Patients who were treated with remdesivir were compared to controls. Remdesivir was administered for 5 days. To adjust for any imbalances in our cohort, a propensity score matched analysis was performed. The aim of our study was to analyze the effect of remdesivir on in-hospital mortality and length of stay (LOS). Results After propensity score matching, 350 patients (175 remdesivir, 175 controls) were included in our analysis. Overall, in-hospital mortality was not significantly different between groups remdesivir 5.7% [10/175] vs. control 8.6% [15/175], hazard ratio 0.50, 95% confidence interval (CI) 0.22–1.12, p = 0.091. Subgroup analysis showed a significant reduction of in-hospital mortality in patients who were treated with remdesivir ≤ 7 days of symptom onset remdesivir 4.2% [5/121] vs. control 10.4% [13/125], hazard ratio 0.26, 95% CI 0.09 to 0.75, p = 0.012 and in female patients remdesivir 2.9% [2/69] vs. control 12.2% [9/74], hazard ratio 0.18 95%CI 0.04 to 0.85, p = 0.03. Patients in the remdesivir group had a significantly longer LOS (11 days vs. 9 days, p = 0.046). Conclusion Remdesivir did not reduce in-hospital mortality in our whole propensity score matched cohort, but subgroup analysis showed a significant mortality reduction in female patients and in patients treated within ≤ 7 days of symptom onset. Remdesivir may reduce mortality in patients who are treated in the early stages of illness..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:134 |
|---|---|
| Enthalten in: |
Wiener klinische Wochenschrift - 134(2022), 23-24 vom: 27. Okt., Seite 883-891 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karolyi, Mario [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Austria |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2022 |
|---|
| doi: |
10.1007/s00508-022-02098-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2080151657 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2080151657 | ||
| 003 | DE-627 | ||
| 005 | 20230518005804.0 | ||
| 007 | tu | ||
| 008 | 230131s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00508-022-02098-9 |2 doi | |
| 035 | |a (DE-627)OLC2080151657 | ||
| 035 | |a (DE-He213)s00508-022-02098-9-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Karolyi, Mario |e verfasserin |0 (orcid)0000-0002-9870-2339 |4 aut | |
| 245 | 1 | 0 | |a Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2022 | ||
| 520 | |a Background Remdesivir is the only antiviral agent approved for the treatment of hospitalized coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen. Studies show conflicting results regarding its effect on mortality. Methods In this single center observational study, we included adult hospitalized COVID-19 patients. Patients who were treated with remdesivir were compared to controls. Remdesivir was administered for 5 days. To adjust for any imbalances in our cohort, a propensity score matched analysis was performed. The aim of our study was to analyze the effect of remdesivir on in-hospital mortality and length of stay (LOS). Results After propensity score matching, 350 patients (175 remdesivir, 175 controls) were included in our analysis. Overall, in-hospital mortality was not significantly different between groups remdesivir 5.7% [10/175] vs. control 8.6% [15/175], hazard ratio 0.50, 95% confidence interval (CI) 0.22–1.12, p = 0.091. Subgroup analysis showed a significant reduction of in-hospital mortality in patients who were treated with remdesivir ≤ 7 days of symptom onset remdesivir 4.2% [5/121] vs. control 10.4% [13/125], hazard ratio 0.26, 95% CI 0.09 to 0.75, p = 0.012 and in female patients remdesivir 2.9% [2/69] vs. control 12.2% [9/74], hazard ratio 0.18 95%CI 0.04 to 0.85, p = 0.03. Patients in the remdesivir group had a significantly longer LOS (11 days vs. 9 days, p = 0.046). Conclusion Remdesivir did not reduce in-hospital mortality in our whole propensity score matched cohort, but subgroup analysis showed a significant mortality reduction in female patients and in patients treated within ≤ 7 days of symptom onset. Remdesivir may reduce mortality in patients who are treated in the early stages of illness. | ||
| 650 | 4 | |a In-hospital mortality | |
| 650 | 4 | |a Austria | |
| 650 | 4 | |a Within 7 days | |
| 650 | 4 | |a Gender differences | |
| 650 | 4 | |a Length of stay | |
| 700 | 1 | |a Kaltenegger, Lukas |4 aut | |
| 700 | 1 | |a Pawelka, Erich |0 (orcid)0000-0003-0199-0539 |4 aut | |
| 700 | 1 | |a Kuran, Avelino |4 aut | |
| 700 | 1 | |a Platzer, Moritz |4 aut | |
| 700 | 1 | |a Totschnig, David |4 aut | |
| 700 | 1 | |a Koenig, Franz |4 aut | |
| 700 | 1 | |a Hoepler, Wolfgang |4 aut | |
| 700 | 1 | |a Laferl, Hermann |0 (orcid)0000-0003-2337-6695 |4 aut | |
| 700 | 1 | |a Omid, Sara |4 aut | |
| 700 | 1 | |a Seitz, Tamara |4 aut | |
| 700 | 1 | |a Traugott, Marianna |4 aut | |
| 700 | 1 | |a Arthofer, Sigrun |4 aut | |
| 700 | 1 | |a Erlbeck, Lea |4 aut | |
| 700 | 1 | |a Jaeger, Stefan |4 aut | |
| 700 | 1 | |a Kettenbach, Alina |4 aut | |
| 700 | 1 | |a Assinger, Alice |4 aut | |
| 700 | 1 | |a Wenisch, Christoph |4 aut | |
| 700 | 1 | |a Zoufaly, Alexander |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Wiener klinische Wochenschrift |d Springer Vienna, 1888 |g 134(2022), 23-24 vom: 27. Okt., Seite 883-891 |w (DE-627)129460036 |w (DE-600)200462-8 |w (DE-576)014823977 |x 0043-5325 |7 nnns |
| 773 | 1 | 8 | |g volume:134 |g year:2022 |g number:23-24 |g day:27 |g month:10 |g pages:883-891 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00508-022-02098-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_4306 | ||
| 951 | |a AR | ||
| 952 | |d 134 |j 2022 |e 23-24 |b 27 |c 10 |h 883-891 | ||